The mask is no longer mandatory in France as of this Monday (02.28.2022) in closed places where it is necessary to access with the vaccination certificate, given the reduction in cases registered in recent weeks. In this way, this protection measure against the coronavirus is no longer imperative in movie theaters, theaters and other shows, in covered sports establishments, as well as in bars and restaurants, which are added to the outdoor places where it was not required from the start. past February 2.
However, it will continue to be compulsory to cover the mouth and nose on public transport, in shops and department stores, churches and religious temples, hospitals and nursing homes, as well as in companies. In all these places it is not necessary to show the pass that indicates that you have been vaccinated to access its interior.
The Government indicated that, on a timely basis, the prefects of a department can impose the mask if the circumstances advise it. In addition, the Executive indicated that close contacts with positives will only need to present one negative test, instead of three.
The test will have to be carried out two days after contact with a positive and the self-tests will be valid, in addition to all the other varieties. In schools, the mask is no longer compulsory in gyms, except for the practice of contact sports, although it is still essential in class for students over 6 years of age and for teachers.
In the last week, there has been a 30 percent drop in positive cases in France and a 25 percent drop in hospitalizations linked to the coronavirus, after the exponential rise registered between the end of December and the beginning of the year linked to the omicron variant. .
The Minister of Health, Olivier Véran, indicated last Thursday that the so-called vaccination pass could end in mid-March, which requires having the complete immunization schedule for access to most public places.
For this, he specified, it will be necessary for the number of patients in intensive care to fall below 1,500, a thousand less than the current ones; that the incidence rate is below 500, 200 less than now; and that the contagion rate remains below 1 for a long time. (EFE)
The vaccines that promise to defeat the coronavirus
Sputnik V, Instituto Gamaleya
The “Russian vaccine” aroused initial mistrust, but it has established itself as an option for some twenty countries, including Argentina, Bolivia and Venezuela. Doubts arose due to its rapid approval, in August 2020, without having finished the trials. However, later studies give high efficacy to this preparation, which uses adenoviral vectors to provoke immunity.
–
–
The vaccines that promise to defeat the coronavirus
BNT162b2, BioNTech/Pfizer
The vaccine from the German firm BioNTech uses a previously unpublished technology: mRNA covered by lipids. Explained simply, the vaccine “mimics” the form of SARS-CoV-2, causing the body’s response. In trials it showed high efficacy, which has been replicated in real conditions. The firm Pfizer acts in the alliance as a manufacturing partner. It is used in twenty countries.
–
–
The vaccines that promise to defeat the coronavirus
mRNA-1273, Modern
The vaccine developed by the National Institute of Allergy and Infectious Diseases, the Biomedical Advanced Research and Development Authority (BARDA) and the firm Moderna uses technology similar to that of BioNTech. In trials, it showed an efficacy close to 95 percent. Unlike BioNTech, this formula can be stored at -20 degrees. It is used in the US and the European Union.
–
–
The vaccines that promise to defeat the coronavirus
AZD1222, Oxford-AstraZeneca
This vaccine developed by British and Swedish experts uses a modified chimpanzee adenovirus as a vector. The trials took place in the UK, Brazil, South Africa, Japan and India, and were interrupted a couple of times due to suspicious deaths. However, its safety and efficacy ranging from 60 to 90 percent have been confirmed. It is used in Brazil, the EU and the United Kingdom.
–
–
The vaccines that promise to defeat the coronavirus
Ad5-nCoV, Cansino Biologics
This Chinese firm’s vaccine uses the common cold adenovirus to introduce an inactivated SARS-CoV-2 protein into the human body, causing an immune response. It has been used in China to inoculate soldiers of the People’s Army, and trials have been carried out in Russia, Pakistan, Mexico, Chile and Argentina. It is currently used in Mexico, Malaysia and Indonesia. Use only one dose.
–
–
The vaccines that promise to defeat the coronavirus
CoronaVac, Sinovac Biotech
Like many vaccines that use inactivated viruses, this formula uses SARS-CoV-2 particles obtained in cultures and inactivated before being injected into the body. The presence of these viruses provokes the immune reaction and prevents the disease from developing. Tested in Brazil, Indonesia, Chile and Turkey, it shows an effectiveness greater than 60 percent.
–
–
The vaccines that promise to defeat the coronavirus
BBV152, Bharat Biotech
Also using inactivated virus, this vaccine developed by Bharat and the Indian Council of Medical Research is known as Covaxin, and has shown 81 percent efficacy in clinical trials. At the time, it sparked controversy for having been inoculated in medical workers when the formula was still in phase I clinical trials. India is now seeking approval in other markets.
–
–
The vaccines that promise to defeat the coronavirus
BBIBP-CorV, Sinopharm
With trials in Argentina, Peru, the United Arab Emirates and other states, this Chinese inactivated virus vaccine has already been approved in Middle Eastern countries. According to studies, it would be 86 percent effective. Sinopharm is in the eye of controversy in Peru for having sent “courtesy vaccines” for politicians and for having donated thousands of dollars to the government.
–
–
The vaccines that promise to defeat the coronavirus
Ad26.COV2.S, Johnson & Johnson
Along with CanSino, it is the only single-dose vaccine to date. It is developed by the Belgian firm Janssen Pharmaceutica, a subsidiary of the American Johnson & Johnson. It can be stored in a normal refrigerator and has shown an efficiency greater than 66 percent. It uses a non-replicative viral vector derived from human adenovirus A26.
